Minoxidil 2% for Eyebrow Enhancement
Efficacy and Tolerability of Minoxidil 2% for Eyebrow Enhancement : A Randomized , Double-blind , Placebo-controlled , Split-face Comparative Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand, 10110
- MFL University Hospital (Bangkok)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male or female aged 18-40 years
- hypotrichosis of eyebrows
- healthy
- informed consent obtained
Exclusion Criteria:
- no underlying diseases
- no alopecia areata or trichotillomania
- no thyroid diseases
- no pregnancy or breast feeding
- no previous eyebrow tattoo, trauma or accident.
- no history of eyebrow or hair medications in 6 months
- no history of minoxidil or its ingredient allergy
- no history of eyebrow surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo is applied twice daily to the other eyebrow.
|
Placebo is applied twice daily to the other eyebrow.
|
|
Experimental: Minoxidil lotion 2%
Minoxidil lotion 2% is applied twice daily to one eyebrow.
|
Minoxidil lotion 2% is applied twice daily to one eyebrow.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The change of global photographic assessment after 16 weeks from baseline
Time Frame: baseline and 16 weeks
|
baseline and 16 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The change of hair diameter after 16 weeks from baseline
Time Frame: baseline and 16 weeks
|
baseline and 16 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The change in number of hairs after 16 weeks from baseline
Time Frame: baseline and 16 weeks
|
baseline and 16 weeks
|
|
Number of participants with adverse events. Adverse events include any skin rashes or symptoms.
Time Frame: 16 weeks
|
16 weeks
|
|
Patient satisfaction by self-assessment questionnaires
Time Frame: 16 weeks
|
16 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Chuchai Tanglertsampan, MD, MFL University Hospital (Bangkok)
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MFL University
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.